WuXi AppTec Shares Soar After First-Half Profit Crushes Estimates

Shares of WuXi AppTec surged on Tuesday after the company reported first-half 2026 financial results that significantly surpassed analyst expectations, driven by robust growth across its business segments. The company's Hong Kong-listed stock climbed 10.7% to close at HK$180.3 following the announcement.

Earnings Beat Drives Rally

WuXi AppTec announced that its revenue for the first half of the year grew by nearly 38.9% year-over-year to approximately RMB 28.9 billion. Net profit attributable to shareholders saw a substantial increase, climbing 33.7% to RMB 11.08 billion.

This profit growth was more than double the 14.5% increase anticipated by a Bloomberg consensus estimate, signaling a major earnings beat that caught investors' attention. On an adjusted non-IFRS basis, which excludes certain one-off items, the company's net profit soared 83.2% compared to the same period a year earlier, highlighting strong underlying operational performance.

Ad

Growth Drivers and Outlook

In a statement, Chairman and CEO Li Ge attributed the strong performance to "strong commercial momentum across various client drug programmes." The company specifically cited high demand related to weight-loss and diabetes drug development as a key growth driver, along with gains in its U.S.-facing business.

Buoyed by the strong first-half results, WuXi AppTec raised its revenue guidance for the full year. The company also announced an interim cash dividend of RMB 5.1 per 10 shares, which is scheduled to be paid in September, signaling confidence in its financial health and a commitment to shareholder returns.